search
Back to results

Human Papilloma Virus (HPV) Self-collection and Women Adherence

Primary Purpose

Cervical Cancer, HPV Infection

Status
Unknown status
Phase
Not Applicable
Locations
Colombia
Study Type
Interventional
Intervention
CERVICAL HPV
SELF SAMPLING HPV
Sponsored by
Instituto Nacional de Cancerologia, Columbia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Cervical Cancer focused on measuring Cervical Cancer, Screening programs, HPV tests

Eligibility Criteria

30 Years - 65 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Women 30-65 years old
  • No history of cytology or any other screening test for cancer of the cervix in the past 5 years
  • Be linked to one of the health providing entities participating in the study
  • Women who sign the informed consent.

Exclusion Criteria:

  • Women 30-65 years old
  • No history of cytology or any other screening test for cancer of the cervix in the past 5 years
  • Be linked to one of the health providing entities participating in the study
  • Women who sign the informed consent.

Sites / Locations

  • Instituto Nacional de Cancerología

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

CERVICAL HPV

SELF SAMPLING HPV ARM 2

SELF SAMPLING HPV ARM 3

Arm Description

Routine screening procedure based on HPV tests with cervical sampling by a health personnel

Screening based on HPV self-testing and colposcopic evaluation

Arm 3: screening based only on HPV self-testing

Outcomes

Primary Outcome Measures

Participation
Number of women that undergo the screening test / total number of women invited.
Adherence
Number of women that undergo the screening test + women who completed the diagnosis and treatment process / total number of women invited + total number of women with a positive screening in follow-up protocols.

Secondary Outcome Measures

Quality of HPV samples
Number of samples suitable for analysis / Total number of samples
CIN2 + rate in the study population
Number of CIN2 + diagnosed / total women screened
CIN2 + rate in population with positive screening
Number of CIN2 + diagnosed / total of women positive at screening

Full Information

First Posted
August 12, 2021
Last Updated
November 29, 2021
Sponsor
Instituto Nacional de Cancerologia, Columbia
search

1. Study Identification

Unique Protocol Identification Number
NCT05059015
Brief Title
Human Papilloma Virus (HPV) Self-collection and Women Adherence
Official Title
Effect of HPV Self-collection in Adherence to Cervical Cancer Screening Algorithms
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Unknown status
Study Start Date
May 1, 2019 (Actual)
Primary Completion Date
September 24, 2020 (Actual)
Study Completion Date
December 3, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Instituto Nacional de Cancerologia, Columbia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Despite declining mortality in high-income countries, cervical cancer continues to be a public health problem in low and middle -income countries. HPV tests have shown a better sensibility and a higher capacity of reducing mortality than cytology based-screening. Greater participation has been demonstrated with the use of HPV self-testing when it is offered to women with a poor screening history; however, it is not clear whether getting tested necessarily translates into a greater adherence to the entire clinical protocol, including diagnosis and treatment of precancerous lesions. The aim of this study is to evaluate the effect of the self-testing techniques on the participation and adherence of women to cervical cancer screening.
Detailed Description
The investigators will perform a randomized clinical trial with three arms including: regular HPV with cytology triage, colpo/biopsy, and treatment if indicated; HPV self-collection without cytology triage but with colpo/biopsy and treatment if indicated, HPV self-collection with immediate treatment for women with positive test results. This study will be carried out in two different settings with differential access to diagnosis and treatment. Two methods will be used for inviting women and collecting samples: mail and door-to-door. Participation (screening uptake) and adherence to the clinical protocol (compliance with diagnosis and treatment) will be evaluated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Cancer, HPV Infection
Keywords
Cervical Cancer, Screening programs, HPV tests

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A randomized clinical trial with three arms will be performed: One group with the routine screening procedure based on HPV tests with cervical sampling by a health personnel ( 3 visits: sampling, colpo/biopsy, treatment of CIN2 +), a second group with a screening based on HPV self-testing and colposcopic evaluation (2 visits: colpo/biopsy, treatment of CIN2 + ); and a third group with a screening based only on HPV self-testing (1 visit: HPV + treatment according to eligibility).
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CERVICAL HPV
Arm Type
Active Comparator
Arm Description
Routine screening procedure based on HPV tests with cervical sampling by a health personnel
Arm Title
SELF SAMPLING HPV ARM 2
Arm Type
Experimental
Arm Description
Screening based on HPV self-testing and colposcopic evaluation
Arm Title
SELF SAMPLING HPV ARM 3
Arm Type
Experimental
Arm Description
Arm 3: screening based only on HPV self-testing
Intervention Type
Diagnostic Test
Intervention Name(s)
CERVICAL HPV
Intervention Description
A screening test with an HPV test is performed by a health professional plus cytology taking, if it reports positive, colposcopy and biopsy are taken, those with a CIN2 + report are directed to receive treatment.
Intervention Type
Diagnostic Test
Intervention Name(s)
SELF SAMPLING HPV
Intervention Description
A screening test is performed with an HPV test by self-testing, if it reports positive, women will receive ablative treatment according to eligibility criteria. If they do not meet the criteria for ablation, they will be referred for excisional treatment.
Primary Outcome Measure Information:
Title
Participation
Description
Number of women that undergo the screening test / total number of women invited.
Time Frame
1 year
Title
Adherence
Description
Number of women that undergo the screening test + women who completed the diagnosis and treatment process / total number of women invited + total number of women with a positive screening in follow-up protocols.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Quality of HPV samples
Description
Number of samples suitable for analysis / Total number of samples
Time Frame
1 year
Title
CIN2 + rate in the study population
Description
Number of CIN2 + diagnosed / total women screened
Time Frame
1 year
Title
CIN2 + rate in population with positive screening
Description
Number of CIN2 + diagnosed / total of women positive at screening
Time Frame
1 year

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Women with no history of cytology or any other screening test for cancer of the cervix in the past 5 years
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women 30-65 years old No history of cytology or any other screening test for cancer of the cervix in the past 5 years Be linked to one of the health providing entities participating in the study Women who sign the informed consent. Exclusion Criteria: Women 30-65 years old No history of cytology or any other screening test for cancer of the cervix in the past 5 years Be linked to one of the health providing entities participating in the study Women who sign the informed consent.
Facility Information:
Facility Name
Instituto Nacional de Cancerología
City
Bogotá
State/Province
Cundinamarca
ZIP/Postal Code
00000
Country
Colombia

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Human Papilloma Virus (HPV) Self-collection and Women Adherence

We'll reach out to this number within 24 hrs